Reflections on 2021 from CEPI CEO Dr Richard Hatchett
21 Dec 2021
By Dr. Richard Hatchett
[Excerpts]
…Whatever its ultimate impact, I believe the emergence of Omicron will come to be seen as a watershed event in the unfolding of the pandemic.  Policymakers and elected officials should pay close attention to what Omicron is telling us.  It encapsulates both how far we have come, even since 2020, and how far we have yet to go.  And it portends our future with COVID….

…But we must also use the momentum the pandemic has created to institutionalize and improve our new response capabilities and to drive the creation of new norms of collective action and accountability.  The response to Omicron, in its positive aspects, exemplifies the ways in which we must be ready to respond to any future threat and the speed and seriousness with which we must act to counter it even as we perform our assessments and gather information.  Omicron’s emergence also provided dramatic backlighting for, and helped propel, the Special Session of the World Health Assembly that convened the week of November 29 to begin deliberations on an international framework or convention on pandemic prevention, preparedness, and response.  Developing such a framework or convention will require sustained diplomacy and likely take years but I am confident the effort will succeed and that the agreements achieved at the Special Session will come to be regarded as foundational.

CEPI will contribute to this momentum in the coming months as we begin to implement our CEPI 2.0 agenda.  We have already announced seed funding for three programs under our Broadly Protective SARS-CoV-2 Vaccine initiative and will soon announce our first awards to support the development of Broadly Protective Betacoronavirus Vaccines.  With Wellcome Leap, we are co-funding 17 different performers under an RNA Readiness and Response (R3) initiative that aims to increase exponentially the number of biologic products that can be designed, developed, and produced every year, reducing their costs and increasing equitable access; and to create a self-sustaining network of manufacturing facilities providing globally distributed, state-of-the-art surge capacity to meet future pandemic needs.  In January, we will put out a call to begin the development of our vaccine libraries and issue a report laying out our thinking about how to achieve the 100-Day Mission – all in the lead-up to our March 2022 Global Pandemic Preparedness Summit, hosted by the government of the United Kingdom.  The Summit will provide an opportunity for world leaders to demonstrate their support for epidemic and pandemic preparedness, the role research and development can play in enabling such preparedness, the institutional capabilities and norms we need to establish to achieve the 100-Day Mission, the value of collective action against common threats, and the overriding imperative to secure access for all to vaccines and other countermeasures….

…Jeremy Farrar, the Director of Wellcome, has said we may still be closer to the beginning of the pandemic than to its end.  Our work through COVAX will and must continue.  And I am sure that 2022 will present many unforetold challenges, just as 2021 did.  But even as we rise to meet whatever 2022 throws at us, we must envision and work toward the future that we desire for the long term.
And how do we accomplish that?  A friend, a journalist, had the opportunity recently to travel to Oslo to attend the ceremony honoring his longtime friend and colleague Maria Ressa, who, with Dmitry Muratov, received the 2021 Nobel Peace Prize for her “efforts to safeguard freedom of expression, which is a precondition for democracy and lasting peace.”  After my friend returned, he called her Nobel Address to my attention as an “important document for our times” (it is; I commend it to you all).  Two statements in her Address have stuck with me:

…We are standing on the rubble of the world that was, and we must have the foresight and courage to imagine what might happen if we don’t act now, and instead, create the world as it should be – more compassionate, more equal, more sustainable…

…Without facts, you can’t have truth. Without truth, you can’t have trust. Without trust, we have no shared reality, no democracy, and it becomes impossible to deal with our world’s existential problems: climate, coronavirus, the battle for truth.

The first statement calls us to recognize our predicament and to have the courage to imagine and begin working towards a better future.  The second reminds us of the conditions required for communities to flourish and to work together to tackle their greatest problems.  Courage, foresight, imagination, facts, trust, and a shared reality:  lacking these, it will be all but impossible to deal with the challenges ahead.  But with them, we can do anything – we can move mountains.

Financial Times
06 January 2022
Covid-19 vaccines
Covid vaccine makers face investor pressure over global access
Asset managers call for pharma executive pay to be linked to equitable distribution of jabs

Drugmakers need to prioritise global access to Covid-19 vaccines and tie management pay to equitable distribution, a group of top international investors has said.

Asset managers Nomura, BMO and GAM are among 65 institutional investors that have written to leading pharmaceutical companies urging them “to make the global availability of vaccines part of the remuneration policy of managers and directors”. The signatories represent more than $3.5tn in assets under management.

“It is clear that currently a large part of the world population still does not have sufficient and equitable access to vaccines,” the investors said in the letter, published on Thursday.

“A pandemic which remains out of control in many parts of the world is and should be at the top of our agenda as global investors, and also for governments and the companies in which we invest.” The letter was sent to the boards of Pfizer, Moderna, AstraZeneca and Johnson & Johnson…

… Drugmakers should prioritise fulfilling contracts for vaccine access schemes Covax and African Vaccine Acquisition Trust “as a matter of urgency”, the investors wrote, and provide transparency and clear monthly supply schedules to these distribution alliances as well as to low- and middle-income countries.

They added that companies should negotiate areas such as delivery swaps with countries that already have high coverage, and commit to greater expertise and technology transfer including licensing rights.

“Pharmaceutical companies have a duty to do their utmost on this but unfortunately we see that they are lagging behind. In addition, the business case is clear: new variants threaten the recovery of economies around the world,” said Rogier Krens, chief investment officer of Achmea Investment Management, the Netherlands-based fund manager that co-ordinated the letter.

Achmea said it would vote against any executive pay packages that did not integrate these objectives. Voting policy among the other signatories may vary. Alex Rowe, portfolio manager at Japan-based Nomura Asset Management, said “prioritising access to vaccines over near-term profits is not only the right thing to do from an ethical standpoint, but the most sustainable long-term approach for these businesses”.

He said this would help lower the risk of new variants developing and of any potential backlash against drugmakers “with regards to their role in limiting the impact on human life”.

The emergence of the highly infectious Omicron coronavirus variant in southern Africa in November highlighted the consequences of failures to vaccinate vast swaths of the world’s population. Global markets tumbled and many countries were forced to bring in new lockdown measures in an effort to halt the spread.

Most of the 65 investors that signed the letter hold small stakes in three of the biggest vaccine manufacturers: Moderna, BioNTech and Pfizer. The largest by some distance is a 0.3 per cent stake in Pfizer held by Canada’s BMO Global Asset Management, worth $1.04bn, while Achmea’s largest pharma holding is a 0.01 per cent stake in J&J valued at $41.1m, according to S&P Capital IQ.

Financial Times
3 January 2022
Opinion
There is a good chance the global impact of coronavirus will ease
The editorial board
Omicron, by far the most contagious coronavirus variant to date, is so rampant around the world that it is easy to feel despondent about the prospects of the pandemic easing — let alone coming to an end — in 2022. But there are good reasons to think that Covid-19’s toll on global health and its wider social and economic impact could wane this year, if governments and health authorities follow appropriate policies and if this volatile virus develops in the way that many scientists believe is most likely.

A debate is growing between those who think new pathogens such as Sars-Cov-2 tend to cause milder disease as time passes and those who say they are just as likely to evolve in a more virulent direction. Without taking sides, it is reasonable to conclude that the interaction between virus and the human immune system means that the more people acquire some protection against severe Covid-19 symptoms through vaccination or infection, the better the outlook. No conceivable descendant of Sars-Cov-2 could have enough mutations in the right places to escape fully the attentions of both antibodies and T-cells generated by prior exposure to an earlier variant.

The top priority is, therefore, to vaccinate the whole world — as it should have been for the past year. Unfortunately, Covid-19 vaccine inequity has never been greater, with just 10 per cent of the population in low-income countries having received at least one jab, according to the World Health Organization, while wealthy nations are rolling out third or even fourth shots. As the WHO says, with global vaccine production close to 1.5bn doses a month, there will be enough for these booster programmes to continue, while directing far more supplies to poorer countries than in 2021, through schemes such as Covax.

Although industrialised nations are justified in protecting their populations with boosters for adults and campaigns to extend vaccination to children, we cannot expect to keep jabbing people every four to six months for very long in the face of new variants. We will have to rely on the immunity provided by annual inoculations — preferably with a new generation of products that are effective against all coronavirus variants — and by repeated exposure to what will sooner or later become an endemic infection.

Governments and regulators must encourage the development of new vaccine technologies to supplement the near duopoly that Moderna and BioNTech/Pfizer enjoy in the developed world with their mRNA products. At the same time, more investment should be directed towards antiviral drugs that could play a bigger role in suppressing symptoms in those who are infected. Recommended Covid-19 vaccines Covid-19 vaccine tracker: the global race to vaccinate

Another vital area that must be reinforced is diagnosis and surveillance. Requirements here range from ensuring enough quick lateral flow tests are available for people to check whether they are infected before meeting others to building up more genomic sequencing capacity worldwide to monitor the emergence of new variants.

Whatever slim chance we might have had at the beginning of 2020 to eliminate Covid-19 has long gone. Efforts to control the pandemic have been justified so far in the context of a global health emergency but they cannot continue indefinitely. The collateral damage — to mental health and wellbeing, social cohesion and the global economy — would be too great. This year the world will have to build up resilience so that we can live with Sars-Cov-2 and its descendants, in a way that causes less disruption while still protecting those who are most vulnerable.

Editor’s Note:
We recognize that the collection of JAMA Viewpoints below are largely focused on U.S. pandemic response policy, programs and imperatives.

JAMA
Online January 6, 2022
Viewpoint
A National Strategy for the “New Normal” of Life With COVID
Ezekiel J. Emanuel, MD, PhD; Michael Osterholm, PhD, MPH; Celine R. Gounder, MD, ScM
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24282
This Viewpoint discusses how US policy makers should address how the nation can move forward as the pandemic persists.
…Conclusions
After previous infectious disease threats, the US quickly forgot and failed to institute necessary reforms. That pattern must change with the COVID-19 pandemic. Without a strategic plan for the “new normal” with endemic COVID-19, more people in the US will unnecessarily experience morbidity and mortality, health inequities will widen, and trillions will be lost from the US economy. This time, the nation must learn and prepare effectively for the future.
The resources necessary to build and sustain an effective public health infrastructure will be substantial. Policy makers should weigh not only the costs but also the benefits, including fewer deaths and lost productivity from COVID-19 and all viral respiratory illnesses. Indeed, after more than 800 000 deaths from COVID-19, and a projected loss of $8 trillion in gross domestic product through 2030,⁸ these interventions will be immensely valuable.

Viewpoint
A National Strategy for COVID-19Testing, Surveillance, and Mitigation Strategies
David Michaels, PhD, MPH; Ezekiel J. Emanuel, MD, PhD; Rick A. Bright, PhD
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24168
This Viewpoint discusses the areas on which the US needs to improve its public health infrastructure in order to reduce COVID-19 transmission and achieve a “new normal”: testing, surveillance, masking, and ventilation.
… Conclusions
To reduce COVID-19 transmission, achieve and sustain a “new normal,” and preempt future emergencies, the nation needs to build and sustain a greatly improved public health infrastructure, including a comprehensive, permanently funded system for testing, surveillance, and mitigation measures that does not currently exist.

Viewpoint
A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics
Luciana L. Borio, MD; Rick A. Bright, PhD; Ezekiel J. Emanuel, MD, PhD
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24165
This Viewpoint proposes a multistep plan that US can implement to achieve a “new normal” of living, in which the combined risk of all viral respiratory illnesses, including COVID-19, does not exceed the risk during prepandemic years.
…Conclusions
There has been tremendous progress in rapidly creating novel COVID-19 vaccines and therapeutics. Nevertheless, these efforts have been insufficient to achieve a “new normal,” in which the combined risk of all viral respiratory illnesses, including COVID-19, does not exceed the risk during pre–COVID-19 years. The US needs investment in variant-specific vaccines, alternative vaccine administration mechanisms, and research into the optimal vaccination strategies. Having effective vaccines are of real value in reducing the spread of COVID-19 and serious illness, but their benefits will be limited without near universal coverage. This coverage can be augmented through additional vaccination requirements. Finally, research needs to be expedited to develop and use effective COVID-19 oral therapeutics. The short window for administration requires a much closer linkage between COVID-19 testing and treatment.

Viewpoint
The First 2 Years of COVID-19 – Lessons to Improve Preparedness for the Next Pandemic
Jennifer B. Nuzzo, DrPH, SM; Lawrence O. Gostin, JD
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.24394
This Viewpoint examines the lessons that the COVID-19 pandemic can provide public health institutions and health care personnel to advance preparedness, detection, and response regarding future pandemics.

Viewpoint
The Pandemic Preparedness Program – Reimagining Public Health
Eli Y. Adashi, MD, MS; I. Glenn Cohen, JD
free access
JAMA. Published online January 6, 2022. doi:10.1001/jama.2021.23656
This Viewpoint reviews the leading objectives of the pandemic preparedness proposal, discusses the outcome of comparable past federal efforts, and emphasizes the imperative of intragovernmental coordination.

Coronavirus [COVID-19] – WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 08 Jan 2022
Confirmed cases :: 298 915 721
Confirmed deaths :: 5 469
Vaccine doses administered: 9 118 223 397

::::::

Weekly epidemiological update on COVID-19 – 06 January 2022
Overview
During the week 27 December 2021 to 2 January 2022, following a gradual increase since October, the global number of new cases increased sharply by 71% as compared to the previous week, while the number of new deaths decreased by 10%. This corresponds to just under 9.5 million new cases and over 41 000 new deaths reported during the last week. As of 2 January, a total of nearly 289 million cases and just over 5.4 million deaths have been reported globally.
All regions reported an increase in the incidence of weekly cases, with the Region of the Americas reporting the largest increase (100%), followed by the South-East Asia Region (78%) and the European Region (65%). The African Region reported a weekly increase in the number of new deaths (22%), while all the other regions reported a decrease as compared to the previous week.

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021
[Full scale view available at title link above]

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca
Press Releases
Vaxzevria significantly boosted antibody levels against Omicron
23 December 2021
:: University of Oxford study supports use of Vaxzevria as third dose booster against Omicron
:: Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in studies from Oxford and Washington Universities
23 December 2021
:: University of Oxford study supports use of Vaxzevria as third dose booster against Omicron
:: Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant

Bharat Biotech
Press Releases
Jan 08: COVAXIN® (BBV152) booster dose study shows promising results
The phase 2, double-blind, randomised controlled COVAXIN® trial demonstrated
long-term safety with no serious adverse events.

BioCubaFarma – Cuba
Últimas Noticias
Casi el 70% de la población cubana ya ha sido inmunizada contra la COVID-19.
20 de Diciembre, 2021

CanSinoBIO
News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News
Jan 5,2022 Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA

Jan 5,2022 Clover Biopharmaceuticals Announces Construction of a New R&D Center in Zhangjiang Hi-Tech Park in Pudong Shanghai

Curevac [Bayer Ag – Germany]
News – No new digest announcements identified

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

Janssen/JNJ
Press Releases
Jan 06, 2022 United States
Real World Evidence Shows Johnson & Johnson COVID-19 Vaccine Demonstrates Durable Protection Against Breakthrough Infection, Hospitalization, and Intensive Care Unit Admission in the United States

Dec 30, 2021 United States
Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
Separate analysis showed Johnson & Johnson COVID-19 vaccine booster generated 41-fold increase in neutralizing antibodies and a 5-fold increase in T-cells against Omicron

Moderna
Press Releases
January 5, 2022
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine

December 27, 2021
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022

December 27, 2021
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna’s COVID-19 Booster Vaccine in 2022

December 20, 2021
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant

Novavax
Press Releases
Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
Dec 31, 2021

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India
Dec 28, 2021

Novavax and SK bioscience Expand Manufacturing Agreement
Dec 23, 2021

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
Dec 22, 2021

Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
Dec 21, 2021

World Health Organization SAGE Issues Interim Recommendations for Novavax COVID-19 Vaccine
Dec 21, 2021

World Health Organization Grants Second Emergency Use Listing for Novavax COVID-19 Vaccine
Dec 20, 2021

Pfizer
Recent Press Releases
01.05.2022
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

01.04.2022
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19

01.04.2022
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

01.03.2022
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older

12.22.2021
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

12.22.2021
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19

Sanofi Pasteur
Press Releases
December 15 2021 Press releases
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation

Serum Institute of India
NEWS & ANNOUNCEMENTS
Tuesday, December 28, 2021
Serum Institute of India and Novavax Receive Emergency Use Authorization in India for COVOVAX™ …

Sinopharm/WIBPBIBP
News – No new digest announcements identified

Sinovac
Press Releases
SINOVAC CoronaVac® Shows Good Safety in Pregnant and Postpartum Women
2021/12/29

South Africa Phase III Clinical Study Shows SINOVAC CoronaVac® Safe for Children as Young as 6 Months
2021/12/2

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

::::::

GSK
Press releases for media – No new digest announcements identified

Merck
News releases
December 24, 2021
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan

December 23, 2021
Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

December 22, 2021
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir

Novartis
News – No new digest announcements identified

SK Biosciences
Press releases
SK bioscience-Novavax Extend Collaboration and Contract Manufacturing Agreements of COVID-19 Vaccine
SK-Novavax amended the Collaboration and License agreement for contract manufacturing of ‘NVX-CoV237…
2021. 12. 24

Valneva
Press Releases
January 5, 2022
Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001

December 23, 2021
Valneva Announces Positive Lot-to-Lot Consistency Trial Results for its Single-Shot Chikungunya Vaccine Candidate

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 08 Jan 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]

COVID-19 Global Targets and Progress Tracker – IMF
The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

Duke – Launch and Scale Speedometer
The Race for Global COVID-19 Vaccine Equity
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution
[accessed 24 July 2021]
See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 08 Jan 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
08 Jan 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 299M total confirmed cases; 5.5M total confirmed deaths
Global vaccines administered: 9.40B
Number of Countries: 30 [30 week ago]
COVAX Allocations Round 4-9 (Number of Doses): 220M
COVAX Delivered (Number of Doses): 260M
Other Delivered (Number of Doses): 330M
Total Delivered (Number of Doses): 590M
Total Administered (Number of Doses): 450M

Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]
https://data.covid19taskforce.com/data
A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.
The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.
Website accessed 08 Jan 2022: https://data.covid19taskforce.com/data The global view below is complemented by country-specific dashboards here.

Our World in Data
Coronavirus (COVID-19) Vaccinations [Accessed 08 Jan 2022]
:: 59.1% of the world population has received at least one dose of a COVID-19 vaccine.
:: 9.4 billion doses have been administered globally, and 29.8 million are now administered each day.
:: Only 8.9% of people in low-income countries have received at least one dose.

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

FDA
Press Announcements
January 7, 2022 – Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months

January 3, 2022 – Coronavirus (COVID-19) Update: FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine

Vaccines and Related Biological Products Advisory Committee– FDA
https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee
No meetings on calendar

::::::

White House [U.S.]
Briefing Room – Selected Major COVID Announcements
Press Briefing by White House COVID-⁠19 Response Team and Public Health Officials
January 05, 2022 Press Briefings

Remarks by President Biden Before Meeting on COVID-⁠19
January 04, 2022 Speeches and Remarks

U.S. Department of State
https://www.state.gov/coronavirus/releases/
Media Notes
Media Note
International Travel Challenges During COVID-19
December 30, 2021

Readout
Secretary Blinken’s Virtual Meeting with Foreign Ministers Regarding the Omicron Variant
December 21, 2021

Press Statement
Supporting Multilateral Responses to the COVID-19 Crisis
Antony J. Blinken December 21, 2021
The United States is providing an additional $580 million from the American Rescue Plan Act to support seven partners who are working tirelessly in our global fight against COVID-19. This funding includes:
$280 million for the World Health Organization (WHO), including $50 million for the Contingency Fund for Emergencies, to help contain the spread of COVID-19, particularly through surveillance and laboratory testing, and support the continuity of essential health services and systems, especially for individuals most at risk;
$170 million to the United Nations Children’s Fund (UNICEF) to expand its efforts to deliver COVID-19 vaccines around the world including to high-risk and vulnerable populations, provide critical COVID-19 commodities, such as Personal Protective Equipment and oxygen equipment, and support education needs in response to the COVID-19 pandemic;
$75 million to the Pan American Health Organization (PAHO) to provide technical cooperation to support implementation and monitoring of COVID-19 vaccinations in the Americas;
$20 million to the United Nations Development Program (UNDP) to help address the socioeconomic impact of COVID-19, including through programs for providing employment services and livelihood support;
$20 million for the United Nations Population Fund (UNFPA) to support its efforts to protect health workers and provide women with safe reproductive and maternal health care to mitigate higher rates of maternal and neonatal mortality and morbidity related to COVID-19;
$10 million to the Food and Agriculture Organization (FAO) to support its efforts to improve health surveillance, early warning, and risk assessment tools for zoonotic diseases; and
$5 million to UN Women to assist their efforts to support women and girls, in all their diversity, during the COVID-19 crisis, including a focus on programs to prevent and respond to gender-based violence.

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency
News & Press Releases 
News: EMA recommends Nuvaxovid for authorisation in the EU (new)
CHMP, Last updated: 20/12/2021
EMA has recommended granting a conditional marketing authorisation for Novavax’s COVID-19 vaccine Nuvaxovid (also known as NVX-CoV2373) to prevent COVID-19 in people from 18 years of age.

News: New treatment for sickle cell disease (new)
CHMP, Last updated: 17/12/2021

News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021 (new)
CHMP, Last updated: 17/12/2021
…The monoclonal antibody Xevudy (sotrovimab) received a positive opinion from the Committee for the treatment of COVID-19. More details are available in a separate news announcement…
…The CHMP gave a positive opinion for Apexxnar (pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)) as prophylaxis against pneumococcal pneumonia and associated invasive disease…

::::::

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
Latest Updates
News
ECDC updates its guidance regarding quarantine and isolation considering the rapid spread of Omicron in the EU/EEA
News story – 7 Jan 2022
Considering the rapid spread of the Omicron variant of concern (VOC), ECDC is proposing options regarding quarantine and isolation, and recommendations that can be adapted and implemented by EU/EEA Member States when resources are limited and when there is high pressure on healthcare systems and other functions in society (e.g. staff shortage and reduced resources). Due to limited scientific evidence on the epidemiological characteristics of Omicron, the proposed options are not evidence based and may imply an additional risk for transmission.

News
Weekly epidemiological update: Omicron variant of concern (VOC) – week 1 (data as of 7 January 2022) EU/EEA
Epidemiological update – 7 Jan 2022
Over the past two weeks, a steep increase in COVID-19 notification rates has been observed in several EU/EEA countries.

::::::

Accessed 08 Jan 2022
https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab

::::::

European Commission
https://ec.europa.eu/commission/presscorner/home/en
Statement 6 January 2022
Statement by President von der Leyen on vaccine sharing in 2021 and targets for 2022
The European Union is the biggest donor of safe and effective COVID-19 vaccines so far.
As Team Europe we have exceeded our vaccine-sharing target in 2021.
We promised to share 250 million doses with low and middle income countries by the end of 2021. And in fact we shared 380 million doses, mostly through COVAX.
More than 255 million of these doses were already delivered to recipient countries. And we will do more.
The Team Europe has promised to share 700 million doses by mid-2022. We are on track to fulfill this promise.
In particular, we will step up our efforts to support Africa where vaccination rates are lower than in other parts of the world.
Because we will only control this global pandemic if we fight it in every corner of the world.

Press release 23 December 2021
EU and US officials discuss efforts to donate and deliver 1.7 billion vaccine doses around the world by mid-2022

Press release 22 December 2021
Rule of Law: Commission launches infringement procedure against Poland for violations of EU law by its Constitutional Tribunal
Today, the European Commission has decided to launch an infringement procedure against Poland because of serious concerns with respect to the Polish Constitutional Tribunal and its recent case law.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

Accessed 08 Jan 2022. Full scale, interactive dashboard available at:
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
The one-shot Sputnik Light vaccine authorized in Tunisia as a universal booster
Press release, 29.12.2021

A study by the Gamaleya Center published at MedRxiv preprint server shows Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to Omicron variant of COVID
Press release, 22.12.2021

Venezuela received 7 mn doses of Sputnik Light booster in the biggest one-time global delivery of the one-shot Russian vaccine
Press release, 21.12.2021

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

07.01.2022 Revised Guidelines for International Arrivals dated 7th January 2022
07.01.2022 List of Countries to be referred to in context of ‘Guidelines for international arrivals’ dated 7th January 2022
07.01.2022 Algorithm for revised guidelines for international arrivals_7th January 2022

Government of India – Press Information Bureau
Latest Press Releases
COVID – 19 Vaccination Update – Day 358
:: More than 2 Cr Vaccine Doses administered among Adolescents between 15-18 age group
:: Schedule for ‘precaution’ dose of Covid-19 released today
:: India’s cumulative vaccination coverage achieves 151.47 crore
:: More than 79 lakh Vaccine doses administered today till 7 pm
Posted On: 08 JAN 2022 8:37PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

No new regulatory/deployment action identified.

Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
https://polioeradication.org/polio-today/polio-now/this-week/

Polio this week as of 05 January 2022
Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
–  Madagascar: One cVDPV1 positive environmental sample

::::::
::::::

Disease Outbreak News (DONs)
23 December 2021 | Yellow Fever – West and Central Africa

23 December 2021 | Hepatitis E Virus – Republic of South Sudan

::::::
::::::

WHO/OCHA Emergencies

Health emergencies list – WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”
Afghanistan crisis [Last apparent update: 18 Oct 2021]

Crisis in Northern Ethiopia [Last apparent update: 1 June 2021]

Ebola outbreak, Democratic Republic of the Congo, 2021 [Last apparent update: 17 Aug 2021]

Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 17 Aug 2021]

Coronavirus disease (COVID-19) pandemic [See COVID above]

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 18 June 2021]

Somalia crisis [Last apparent update: 24 March 2018]

Nigeria crisis [Last apparent update: 1 Oct 2021]

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 17 Aug 2021]

Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

Ebola outbreak: West Africa, 2014-2016 [Last apparent update: 17 Aug 2021]

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 13 September 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: ICCT Real-Time Response Overview Situation Report (23 December 2021)

Northern Ethiopia
Ethiopia – Northern Ethiopia Humanitarian Update Situation Report, 6 January 2022
Situation Report
HIGHLIGHTS
In Amhara, 30 hospitals, 280 health centres and 890 health posts have resumed provision of basic health services.
Food Cluster partners voiced concern over the risk of spoilage and infestation of humanitarian food stocks in Semera, Afar Region, due to the harsh weather conditions and the urgent need to bring in fumigants (currently unavailable in the region) to treat stored stock.
As of 3 January, food partners have around only 10000L of fuel left in Tigray. At least 60000L of fuel are needed to dispatch around 4000 MT of food currently available in Mekelle.
A measles campaign started on 1 January in Mekelle, targeting 1.7 million children under five years of age.

::::::
::::::

WHO & Regional Offices [to 08 Jan 2022]
https://www.who.int/
Selected News, Statements
23 December 2021
Departmental news
Achieving 70% COVID-19 Immunization Coverage by Mid-2022
[See Perspectives above for full text]

22 December 2021
Statement
Interim statement on booster doses for COVID-19 vaccination

22 December 2021
News release
From vaccines to vaccinations: seventh meeting of the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics

21 December 2021
Departmental news
US FDA approved cabotegravir extended-release – the first long-acting injectable option for HIV pre-exposure prophylaxis

21 December 2021
Departmental news
WHO lists 10th COVID-19 vaccine for emergency use : Nuvaxovid

20 December 2021
Departmental news
Latest child mortality estimates reveal world remains off track to meeting Sustainable Development Goals

20 December 2021
Departmental news
Novavax Covid-19 vaccine recommendations for use

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Meningitis outbreak in Democratic Republic of the Congo declared over 24 December 2021

WHO Region of the Americas PAHO
:: 29 Dec 2021 COVID-19 cases increase 50% in the Americas in the last week
The region reports the biggest rise in cases worldwide with holiday period set to drive up numbers, PAHO warns, urging countries to continue vaccination campaigns and implementation of public health measures. Washington, DC, December 29, 2021 (PAHO)- Pan American Health Organization (PAHO) data show that COVID-19 cases increased 50% and deaths 11…
:: 23 Dec 2021 PAHO welcomes first WHO emergency use listing of COVID-19 vaccine produced in Latin America
Approval will increase vaccine availability as pandemic persists Washington, D.C., 23 December 2021 (PAHO) – The Pan American Health Organization (PAHO) welcomed the WHO listing today of an AstraZeneca vaccine jointly produced by Argentina and Mexico – the first such decision for a COVID-19 vaccine manufactured in Latin America. The vaccine,…

WHO South-East Asia Region SEARO
:: 8 January 2022 News release Strict implementation of public health and social measures a must to arrest the surge: WHO

WHO European Region EURO
No new digest content identified

WHO Eastern Mediterranean Region EMRO
:: German donation supports nationwide monitoring of COVID-19 variants in Islamic Republic of Iran
6 January 2022
:: Statement by WHO’s Regional Director for the Eastern Mediterranean on COVID-19
Cairo, 22 December 2021 – A year ago, the COVID-19 vaccine rollout had brought us hope that we could end the acute phase of the pandemic by the end of 2021. Instead, as we enter the third year of the pandemic, the world remains very much in its grip. Globally, COVID-19 has so far claimed more than five million lives…
::Inequitable COVID-19 vaccination coverage in the Eastern Mediterranean Region is a missed opportunity to protect people from severe disease and death
Cairo, 20 December 2021– As 2021 comes to an end, the gap in COVID-19 vaccination coverage between countries of the Eastern Mediterranean Region widens alarmingly  As of 14 December 2021, over 500 million doses of COVID-19 vaccine have been administered in the Region, an average of 65 doses per 100 population. However, high- and upper-middle-income countries have administered about twice the…

WHO Western Pacific Region
No new digest content identified

::::::

WHO Events
https://www.who.int/news-room/events/2
[Selected]
19 January 2022
Extraordinary meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) – 19 January 2022

13 January 2022
Seventh meeting of the WHO Council on the Economics of Health for All

11 January 2022
COVID-19 Case Management Webinar Series: COVID-19 and pregnancy

::::::

New WHO Publications
https://www.who.int/publications/i
Selected Titles
6 January 2022
Mekong Malaria Elimination: epidemiology summary, volume 15, July–September 2021

30 December 2021
Together on the road to evidence-informed decision-making for health in the post-pandemic era: a draft call for action
Overview
The EVIPNet Call for Action for sustainable evidence-policy-society-systems was launched at the WHO Global Evidence-to-Policy Summit in November 2021, and received wide encouragement and support from global partners, multisectoral stakeholders and EVIPNet members. Existing EVIPNet country teams and partner organizations will provide additional support taking the Call for Action forward.

23 December 2021
An implementation guide for the management of COVID-19 on board cargo ships and fishing vessels

22 December 2021
WHO recommendations on mask use by health workers, in light of the Omicron variant of concern: WHO interim…

22 December 2021
COVID-19 infection prevention and control living guideline: mask use in community settings, 22 December…

20 December 2021
Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19

20 December 2021

Annexes to the interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19

CDC/ACIP [U.S.] [to 08 Jan 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements [Selected]
Telebriefing on COVID-19 Update Friday, January 7, 2022

CDC Media Telebriefing: Update on COVID-19 Thursday, January 6, 2022
CDC Reports Increase in Human Rabies Cases Linked to Bats in the U.S. Thursday, January 6, 2022

CDC Expands Booster Shot Eligibility and Strengthens Recommendations for 12-17 Year Olds Wednesday, January 5, 2022

CDC Recommends Pfizer Booster at 5 Months, Additional Primary Dose for Certain Immunocompromised Children Tuesday, January 4, 2022

CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population Monday, December 27, 2021

ACIP Meetings
Next Meeting – January 12, 2022,  10:00am – 3:30pm Eastern
This meeting is virtual. No registration is required to watch the webcasts.
:: Draft Agenda – January 12, 2022pdf icon
:: Webcast Link
:: Federal Register

Presentation Slides
ACIP past meeting presentations: January 5, 2022

MMWR News Synopsis Friday, January 7, 2022
Selected Content
:: Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021
:: Previously Released: Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021

Coronavirus Disease 2019 (COVID-19)– CDC
Approximately 25 announcements/reports/data summaries.
1/7/22 EARLY RELEASE: Risk for Newly Diagnosed Diabetes 30 Days After SARS-CoV-2 Infection Among Persons Aged 18 years — United States, March 1, 2020–June 28, 2021
1/7/22 EARLY RELEASE: Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
1/7/22 Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 07 Jan 2022 06:00:00 EST
1/7/22 COVID-19 Vaccine Booster Shot
1/7/22 COVID-19 Vaccines for Moderately to Severely Immunocompromised People
1/7/22 Staffing Resources
1/7/22 Information about the Moderna COVID-19 Vaccine
1/7/22 Different COVID-19 Vaccines
1/7/22 Infection Prevention and Control Assessment Tool for Nursing Homes Preparing for COVID-19
1/7/22 COVID Data Tracker Weekly Review
1/6/22 CDC Media Telebriefing: Update on COVID-19
1/6/22 Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series — 465 Health Care Facilities, United States, December 2020–October 2021
1/6/22Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021
1/6/22 Overview of COVID-19 Isolation for K-12 Schools
1/6/22 Overview of COVID-19 Quarantine for K-12 Schools
1/6/22 Responding to COVID-19 Cases in K-12 Schools: Resources for School Administrators
1/6/22 What You Should Know About COVID-19 Testing in Schools
1/6/22 Guidance for COVID-19 Prevention in Kindergarten (K)-12 Schools
1/6/22 Information about the Pfizer-BioNTech COVID-19 Vaccine
1/6/22 Schools and Childcare Programs
1/5/22 CDC Expands Booster Shot Eligibility and Strengthens Recommendations for 12-17 Year Olds

Africa CDC [to 08 Jan 2022]
http://www.africacdc.org/
News
Outbreak Brief 103: Coronavirus Disease 2019 (COVID-19) Pandemic
4 Jan 2022

China CDC http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 08 Jan 2022]
http://en.nhc.gov.cn/
News
Jan 8: Daily briefing on novel coronavirus cases in China
On Jan 7, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 159 new cases of confirmed infections.

Over 7 mln vaccine doses administered in SW China’s Tibet
2022-01-07

National Medical Products Administration – PRC [to 08 Jan 2022]
http://english.nmpa.gov.cn/
News
Over 2.87b COVID-19 vaccine doses administered on Chinese mainland
2022-01-07
Over 2.87 billion COVID-19 vaccine doses had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Jan 6.

Chinese mainland reports 116 locally transmitted COVID-19 cases
2022-01-07
The Chinese mainland on Thursday reported 116 new locally transmitted COVID-19 cases, the National Health Commission said in its daily report on Jan 7.

CCDC Weekly Reports: Current Volume (4)
2022-01-07 / No. 1
View  PDF of this issue
:: Outbreak Reports: A H9N2 Human Case and Surveillance of Avian Influenza Viruses in Live Poultry Markets — Huizhou City, Guangdong Province, China, 2021
:: Outbreak Reports: Three Cases Infected with Avian Influenza A(H5N6) Virus — Chongqing Municipality, China, January–September, 2021

::::::

 
 
Organization Announcements
Editor’s Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Airfinity
https://www.airfinity.com/insights
INSIGHTS & COMPANY NEWS
No new digest content identified.
 
 
Paul G. Allen Frontiers Group [to 08 Jan 2022]
https://alleninstitute.org/news-press/
News
New technique sorts out what different kinds of neurons do in the brain
January 7, 2022
Study pinpoints a mouse neuron’s role in sensing touch
 
 
BARDA – U.S. Department of HHS [to 08 Jan 2022]
https://www.phe.gov/about/barda/Pages/default.aspx
News
No new digest content identified.
 
 
BMGF – Gates Foundation [to 08 Jan 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.
 
 
Bill & Melinda Gates Medical Research Institute [to 08 Jan 2022]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
 
 
CARB-X [to 08 Jan 2022]
https://carb-x.org/
News
No new digest content identified.
 
 
Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 08 Jan 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – January 2022 is now posted here
 
 
CEPI – Coalition for Epidemic Preparedness Innovations [to 08 Jan 2022]
http://cepi.net/
Latest News
Reflections on 2021 from CEPI CEO Dr Richard Hatchett
21 Dec 2021
By Dr. Richard Hatchett
CEPI CEO Dr Richard Hatchett offers his personal reflections on the events of the past year, and looks to the challenges ahead as the world responds to Omicron and prepares for the threat of future pandemics.
[See Perspectives above for excerpts]
 
 
DARPA – Defense Advanced Research Projects Agency [U.S.] [to 08 Jan 2022
https://www.darpa.mil/news
News
No new digest content identified.
 
 
Duke Global Health Innovation Center [to 08 Jan 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.
 
 
EDCTP [to 08 Jan 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.
 
 
Emory Vaccine Center [to 08 Jan 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.
 
 
European Vaccine Initiative [to 08 Jan 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.
 
 
Fondation Merieux [to 08 Jan 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.
 
 
Gavi [to 08 Jan 2022]
https://www.gavi.org/
News Releases
COVAX awarded 2021 North-South Prize for enhancing global equitable access to COVID-19 vaccines
Geneva, 21 December 2021 – The COVAX Facility has been awarded the 2021 North-South Prize of the Council of Europe in recognition of its efforts to ensure that COVID-19 vaccines are available worldwide, including in low-income countries, and for striving for a more equitable world to protect people’s lives.
…The North-South Prize of the Council of Europe is awarded each year to two nominees, one from the North and one from the South, for their exceptional commitment to promoting North-South solidarity…

GHIT Fund [to 08 Jan 2022]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.
 
 
Global Fund [to 08 Jan 2022]
https://www.theglobalfund.org/en/news/
News & Stories
News
Global Fund Praises Norway’s Leadership in Global Fight Against COVID-19
22 December 2021
The Global Fund praises Norway’s leadership in the global fight against COVID-19 after its decision to allocate NOK 440 million (US$49.1 million) to the Global Fund’s COVID-19 Response Mechanism (C19RM). This new contribution, which is on top of the …

News
Global Fund Applauds Luxembourg’s Contribution to the COVID-19 Response Mechanism
21 December 2021
The Global Fund to Fight AIDS, Tuberculosis and Malaria applauds the decision by Luxembourg to contribute €2 million to the Global Fund’s COVID-19 Response Mechanism.
 
 
Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 08 Jan 2022]
https://www.glopid-r.org/news/
News
No new digest content identified.
 
 
Hilleman Laboratories [to 08 Jan 2022]
http://www.hillemanlabs.org/
News & Insights
No new digest content identified.
 
 
HHMI – Howard Hughes Medical Institute [to 08 Jan 2022]
https://www.hhmi.org/news
Press Room
Research Jan 6 2022
Cystic Fibrosis Drugs Can Be ‘Life-Changing’ For Patients. New Images Reveal How These Molecules Work
A mutated protein causes the genetic disease cystic fibrosis. Now, researchers have solved the structure of the protein and how certain drugs bind to it, unveiling their mode of action.
 
 
Human Vaccines Project [to 08 Jan 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.
 
 
IAVI [to 08 Jan 2022]
https://www.iavi.org/newsroom
Latest News
FEATURES
January 5, 2022
IAVI remembers Archbishop Desmond Tutu
The archbishop advocated for the human rights of people living with HIV and tuberculosis
 
 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.
 
 
ICRC [to 08 Jan 2022]
https://www.icrc.org/en/whats-new
Selected News Releases, Statements, Reports
Egypt: ICRC donates protective equipment to health ministry to support fight against COVID-19
The ICRC donation, worth 1 million Egyptian pounds, includes FFP2/N95 masks, protective coveralls, examination gloves, surgical gloves, body bags, and non-touch thermometers.The PPE will be sent to the health facilities in the governorates of Ismailia and North Sinai. This comes as part of the continued cooperation between the ICRC and the health ministry to support the
20-12-2021 | News release

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.
 
 
IFRC [to 08 Jan 2022]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
Philippines: Mounting health crisis after super typhoon
06/01/2022 | Press release
 
 
Institut Pasteur [to 08 Jan 2022]
https://www.pasteur.fr/en/press-area
Press Documents
Press release 23.12.2021
COVID-19 – Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose
The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many…
 
 
IOM / International Organization for Migration [to 08 Jan 2022]
http://www.iom.int/press-room/press-releases
News – Selected
News 21 Dec 2021
Global Diaspora Week: Maximizing Diaspora Contributions in Development

News 21 Dec 2021
Returning Female Migrants Face More Reintegration Challenges than Men: IOM Study
 
 
ISC / International Science Council [to 08 Jan 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
News
No new digest content identified.
 
 
IVAC [to 08 Jan 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.
 
 
IVI [to 08 Jan 2022]
http://www.ivi.int/
IVI News & Announcements
2021 Year in Review
[Undated]

IVI and Mozambique’s INS launch mix-and-match COVID-19 vaccine study
:: Study will assess the safety and immunogenicity of a heterologous regimen of two approved COVID-19 vaccines in adults
:: Aims to mitigate vaccine shortages and support flexible immunization programs
December 20, 2021
 
 
Johns Hopkins Center for Health Security [to 08 Jan 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
Johns Hopkins Center for Health Security’s COVID-19 Testing Toolkit Expands in Second Year
December 21, 2021
 
 
MSF/Médecins Sans Frontières [to 08 Jan 2022]
http://www.msf.org/
Latest [Selected Announcements]
South Sudan
Hundreds of thousands of people in dire conditions months after floods
Project Update 7 Jan 2022

Chad
“If the rain abandons us again, we don’t know what we will do”
Project Update 6 Jan 2022

Refugees, IDPs and people on the move
MSF leaves Polish border after being blocked from assisting people
Press Release 6 Jan 2022

Chad
Tens of thousands of people flee Cameroon as violence spreads
Project Update 4 Jan 2022
 
 
National Academy of Medicine – USA [to 08 Jan 2022]
https://nam.edu/programs/
Selected News/Programs/Events
No new digest content identified.
 
 
National Academy of Sciences – USA [to 08 Jan 2022]
http://www.nasonline.org/news-and-multimedia/
News
No new digest content identified.
 
 
National Vaccine Program Office – U.S. HHS [to 08 Jan 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
National Vaccine Advisory Committee [NVAC] 2022 Meetings
February 10-11, 2022
 
 
NIH [to 08 Jan 2022]
http://www.nih.gov/news-events/news-releases
News Releases
COVID-19 vaccination associated with a small, temporary increase in menstrual cycle length, suggests NIH-funded study
January 6, 2022 — The authors noted that menstrual cycles typically vary a small amount from month to month.

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention
December 21, 2021 — Approval marks pivotal expansion of HIV prevention options in the United States.
 
 
OECD [to 08 Jan 2022]
http://www.oecd.org/newsroom/publicationsdocuments/bydate/
Newsroom
No new digest content identified.
 
 
PATH [to 08 Jan 2022]
https://www.path.org/media-center/
Press Releases
No new digest content identified.
 
 
Sabin Vaccine Institute [to 08 Jan 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.
 
 
UNAIDS [to 08 Jan 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
6 January 2022
New indicators added to Key Populations Atlas
The UNAIDS Key Populations Atlas is an online tool that provides a range of information about members of key populations—sex workers, gay men and other men who have sex with men, people who inject drugs, transgender people and prisoners—worldwide, together with information about people living with HIV.
Information about gay men and other men who have sex with men has been expanded with the inclusion of 11 new indicators from the EMIS and LAMIS projects. Under funding from the European Commission, EMIS-2017 collected data from gay men and other men who have sex with men in 50 countries between October 2017 and January 2018. LAMIS is the Latin American version of EMIS and finished data collection across 18 additional countries in May 2018.
The 11 new indicators shown in the Key Population Atlas—on syphilis, symptomatic syphilis, gonorrhoea, symptomatic gonorrhoea, chlamydia, symptomatic chlamydia, sexually transmitted infections testing, syphilis partner notification, gonorrhoea partner notification and hepatitis A and B vaccination—were chosen because of their high relevance to the communities…

UNHCR Office of the United Nations High Commissioner for Refugees [to 08 Jan 2022]
http://www.unhcr.org/en-us/media-centre.htmlS
Selected News Releases, Announcements
Pakistan concludes ‘drive’ to issue smartcards to registered Afghan refugees
4 Jan 2022

UNICEF [to 08 Jan 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
12/31/2021
Grave violations of children’s rights in conflict on the rise around the world, warns UNICEF
Less than half of parties to conflict globally have committed to protect children
 
 
Unitaid [to 08 Jan 2022]
https://unitaid.org/
Featured News
No new digest content identified.
 
 
USAID [to 08 Jan 2022]
https://www.usaid.gov/news-information/press-releases/2021
Selected Press Releases, Statements, Announcements
Administrator Samantha Power’s Meeting with Director of the Africa Centres for Disease Control and Prevention Dr. John Nkengasong
January 4, 2022
Today, Administrator Samantha Power met with Dr. John Nkengasong, the Director of the Africa Centres for Disease Control and Prevention (Africa CDC). They discussed the recently announced whole-of-government effort, the Initiative for Global Vaccine Access (Global VAX), to accelerate global efforts to turn COVID-19 vaccines into vaccinations through expanded vaccine readiness, delivery support, and enhanced coordination. Dr. Nkengasong provided his perspective on the country capacity and political will needed to significantly ramp up vaccine access and delivery across the African continent. The Administrator and Dr. Nkengasong agreed on the importance of close collaboration between the U.S. government and the Africa CDC in achieving Global VAX goals.

Administrator Samantha Power at the Swearing-in Ceremony for Atul Gawande, Assistant Administrator to the Bureau for Global Health
January 4, 2022
In addition to his focus on strengthening health systems, Atul will lead efforts to prevent needless child and maternal deaths, respond to infectious disease threats and expand our family planning programming to better address the health and rights of women and girls. And critically, Atul will bring his characteristic mentorship and empathy to the nine offices of the Global Health Bureau as they work to spread health equity around the world.
 
 
Vaccine Equity Cooperative [nee Initiative] [to 08 Jan 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.
 
 
Vaccination Acceptance & Demand Initiative [Sabin) [to 08 Jan 2022]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.
 
 
Vaccine Confidence Project [to 08 Jan 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia [to 08 Jan 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
TWiV 844: Paul Offit on children, COVID, and boosters
December 19, 2021
Paul Offit returns to TWiV to discuss new CDC guidance on J&J vaccine, why children should be immunized against COVID-19, and whether or not booster doses are scientifically justified.
 
 
Wellcome Trust [to 08 Jan 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.
 
 
The Wistar Institute [to 08 Jan 2022]
https://www.wistar.org/news/press-releases
Press Releases
Jan. 5, 2022
Wistar and Stanford Medicine to Begin Phase 2 Clinical Trial of VK-2019 in Patients with Epstein-Barr Virus (EBV)-Positive Advanced Nasopharyngeal Carcinoma
Phase 2 clinical trial to evaluate novel anticancer drug candidate.
 
 
WFPHA: World Federation of Public Health Associations [to 08 Jan 2022]
https://www.wfpha.org/
Latest News – Blog
Public Health Leadership Coalition: A Call to Action
Dec 20, 2021
Global challenges can only be overcome through global efforts and the adoption of appropriate global approaches to address health threats at the animal, human, and environmental interfaces.
Global public health leaders, working within the framework of the World Federation of Public Health Associations, have called for actions to promote equity, public health leadership and global coordination to address pressing global health challenges, including the COVID-19 pandemic and other health threats.
 
 
World Bank [to 08 Jan 2022]
http://www.worldbank.org/en/news/all
Selected News, Announcements
World Bank Prices First CAD Sustainable Development Bond of 2022 and Highlights Health and COVID-19 Response Efforts
WASHINGTON, D.C., January 6, 2022 – The World Bank (International Bank for Reconstruction and Development, IBRD, Aaa/AAA) today priced a new 5-year CAD 1.5 billion benchmark that matures on January 19…
Date: January 06, 2022 Type: Press Release

World Bank Supports Burundi’s Response to COVID-19
WASHINGTON, December 22, 2021 – The World Bank Group approved today US$60 million in additional funding for the COVID-19 Preparedness and Response Project in Burundi to help the Government prevent, detect…
Date: December 22, 2021 Type: Press Release

World Bank’s Operational Response to COVID-19 (Coronavirus) in East Asia and the Pacific
The World Bank Group is taking broad, fast action to help developing countries strengthen their pandemic response, increase disease surveillance, improve public health interventions, and help the private…
Date: December 22, 2021 Type: Brief

Joint Statement of the Multilateral Leaders Taskforce on Scaling Covid-19 Tools, December 17, 2021: “From Vaccines to Vaccinations”
Washington, December 22, 2021 — The heads of the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization held high-level consultations with…
Date: December 22, 2021 Type: Statement
[See Perspectives above for detail]
 
 
World Organisation for Animal Health (OIE) [to 08 Jan 2022]
https://www.oie.int/en/media/news/
Press Releases, Statements
No new digest content identified.
 
 
WTO – World Trade Organisation [to 08 Jan 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
International organizations discuss how to improve access to COVID vaccines, countermeasures
22 December 2021
The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization held on 17 December high-level consultations with UNICEF and Gavi aimed at increasing access to COVID-19-related vaccines and other critical medical countermeasures in low— and lower-middle-income countries. The four agency heads — Kristalina Georgieva (IMF), David Malpass (World Bank), Dr Tedros Adhanom Ghebreyesus (WHO) and Dr Ngozi Okonjo-Iweala (WTO) — issued a joint statement on behalf of the Multilateral Leaders Task Force.
[See Perspectives above for detail]

::::::

ARM [Alliance for Regenerative Medicine] [to 08 Jan 2022]
https://alliancerm.org/press-releases/
Selected Press Releases
No new digest content identified.
 
 
BIO [to 08 Jan 2022]
https://www.bio.org/press-releases
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network [to 08 Jan 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.
 
 
ICBA – International Council of Biotechnology Associations [to 08 Jan 2022]
https://internationalbiotech.org/news/
News
No new digest content identified.
 
 
IFPMA [to 08 Jan 2022]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.
 
 
International Alliance of Patients’ Organizations – IAPO [to 08 Jan 2022]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.
 
 
PhRMA [to 08 Jan 2022]
http://www.phrma.org/
Latest News [Selected]
No new digest content identified.

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Infection Control
January 2022 Volume 50 Issue 1 p1-122
http://www.ajicjournal.org/current

Major Articles
Estimating pediatric cases of COVID-19 over time in the United States: Filling in a gap in public use data
Timothy L Wiemken, Samson L Niemotka, Jacob A Clarke, Christopher G Prener, Ana Santos Rutschman
Published online: October 27, 2021

American Journal of Infection Control
January 2022 Volume 50 Issue 1 p1-122
http://www.ajicjournal.org/current

Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study
Renuka Ananth Kalyan Kadali, Ravali Janagama, Siva H. Yedlapati, …Hanumantha R. Jogu, Shailaja Racherla, Isha Shah
Published online: October 27, 2021
p8-14
Open Access

American Journal of Infection Control
January 2022 Volume 50 Issue 1 p1-122
http://www.ajicjournal.org/current

COVID-19 vaccination hesitancy among health care workers, communication, and policy-making
Stephanie M. Toth-Manikowski, Eric S. Swirsky, Rupali Gandhi, Gina Piscitello
Published online: October 12, 2021
p20-25

American Journal of Public Health
January 2022 112(1)
http://ajph.aphapublications.org/toc/ajph/current

NOTES FROM THE FIELD
Deployment of Health Equity Strike Teams to Address COVID-19 Vaccine Disparities in Arkansas, 2021
Health Service Delivery, Immunization/Vaccines, Access to Care
Austin Porter, Samantha Wells, Chimfumnanya Smith, Namvar Zohoori, George Pro and Michelle R. Smith
112(1), pp. 29–33

Annals of Internal Medicine
December 2021 Volume 174, Issue 12
http://annals.org/aim/issue

Original Research
Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020
FREE
Meredith S. Shiels, PhD, MHS, Anika T. Haque, MPH, Emily A. Haozous, PhD, RN, Paul S. Albert, PhD,
Pages:1693–1699

Annals of Internal Medicine
December 2021 Volume 174, Issue 12
http://annals.org/aim/issue 

Special Articles
COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology
FREE
Christine Laine, MD, MPH, Deborah Cotton, MD, MPH, Darilyn V. Moyer, MD
Pages:1733–1734

Annals of Internal Medicine
December 2021 Volume 174, Issue 12
http://annals.org/aim/issue

Measuring the COVID-19 Mortality Burden in the United States – A Microsimulation Study
FREE

Julian Reif, PhD, Hanke Heun-Johnson, PhD, Bryan Tysinger, PhD, Darius Lakdawalla, PhD
Pages:1700–1709

Annals of Internal Medicine
December 2021 Volume 174, Issue 12
http://annals.org/aim/issue

Original Research
Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020
FREE
Meredith S. Shiels, PhD, MHS, Anika T. Haque, MPH, Emily A. Haozous, PhD, RN, Paul S. Albert, PhD,
Pages:1693–1699

BMJ Global Health
January 2022 – Volume 7 – 1
https://gh.bmj.com/content/7/1

Original research
Ethical health security in the age of antimicrobial resistance (7 January, 2022)
Kari Pahlman, Anson Fehross, Greg J Fox, Diego S Silva

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 08 Jan 2022)

Two decades of regional trends in vaccination completion and coverage among children aged 12-23 months: an analysis of the Uganda Demographic Health Survey data from 1995 to 2016
Childhood vaccination is an important public health intervention but there is limited information on coverage, trends, and determinants of vaccination completion in Uganda at the regional level. We examined tr…
Authors: Gerald Okello, Jonathan Izudi, Immaculate Ampeire, Frehd Nghania, Carine Dochez and Niel Hens
Citation: BMC Health Services Research 2022 22:40
Content type: Research
Published on: 7 January 2022

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 08 Jan 2022)

Economic impact of switching from partially combined vaccine “Pentaxim® and hepatitis B” to fully combined vaccine “Hexaxim®” in the Malaysian National Immunization Program
The decision to implement new vaccines should be supported by public health and economic evaluations. Therefore, this study was primarily designed to evaluate the economic impact of switching from partially co…
Authors: Syed Mohamed Aljunid, Lama Al Bashir, Aniza Binti Ismail, Azimatun Noor Aizuddin, S. A. Zafirah Abdul Rashid and Amrizal Muhammad Nur
Citation: BMC Health Services Research 2022 22:34
Content type: Research
Published on: 5 January 2022

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 08 Jan 2022)

Poliovirus immunity among adults in the Democratic Republic of the Congo: a cross-sectional serosurvey
Vaccination efforts to eradicate polio currently focus on children under 5 years of age, among whom most cases of poliomyelitis still occur. However, in the Democratic Republic of the Congo (DRC), an outbreak …
Authors: Vivian H. Alfonso, Arie Voorman, Nicole A. Hoff, William C. Weldon, Sue Gerber, Adva Gadoth, Megan Halbrook, Amelia Goldsmith, Patrick Mukadi, Reena H. Doshi, Guillaume Ngoie-Mwamba, Trevon L. Fuller, Emile Okitolonda-Wemakoy, Jean-Jacques Muyembe-Tamfum and Anne W. Rimoin
Citation: BMC Infectious Diseases 2022 22:30
Content type: Research
Published on: 5 January 2022

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 08 Jan 2022)

Immunisation status of children and adolescents with a new diagnosis of inflammatory bowel disease
Patients with Inflammatory Bowel Disease (IBD) are at increased risk of serious infections, including vaccine preventable diseases. Current evidence suggests uptake of additional recommended special risk vacci…
Authors: Timothy Ford, Margie Danchin, Alissa McMinn, Kirsten Perrett, George Alex and Nigel W. Crawford
Citation: BMC Infectious Diseases 2022 22:6
Content type: Research
Published on: 4 January 2022

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 08 Jan 2022)

A systematic approach to the disclosure of genomic findings in clinical practice and research: a proposed framework with colored matrix and decision-making pathways
Whether and how to disclose genomic findings obtained in the course of genomic clinical practice and medical research has been a controversial global bioethical issue over the past two decades. Although severa…
Authors: Kenji Matsui, Keiichiro Yamamoto, Shimon Tashiro and Tomohide Ibuki
Citation: BMC Medical Ethics 2021 22:168
Content type: Research
Published on: 25 December 2021

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 08 Jan 2022)

Predicting human papillomavirus vaccine uptake in men who have sex with men the influence of vaccine price and receiving an HPV diagnosis
To understand how human papillomavirus (HPV) screening results, HPV-related knowledge and attitudes are related to vaccination intention in three cost ranges and the actual vaccination behavior in a community …
Authors: Po-Yi Yao, Chung-Ying Lin, Nai-Ying Ko, Huachun Zou, Chia-Wen Lee and Carol Strong
Citation: BMC Public Health 2022 22:28
Content type: Research article
Published on: 6 January 2022

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 08 Jan 2022)

Comparison of hesitancy between COVID-19 and seasonal influenza vaccinations within the general Hungarian population: a cross-sectional study
The willingness to get COVID-19 or seasonal influenza vaccines has not yet been thoroughly investigated together, thus, this study aims to explore this notion within the general adult population.
Authors: Viktor Dombrádi, Tamás Joó, Gergely Palla, Péter Pollner and Éva Belicza
Citation: BMC Public Health 2021 21:2317
Content type: Research
Published on: 23 December 2021

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 08 Jan 2022)

Medicines and vaccines supply chains challenges in Nigeria: a scoping review
Medicines and vaccines supply chains represent critical systems for realising one of the major targets of the United Nations’ third Sustainable Development Goals (SDGs)—access to safe, effective, quality, and

Authors: Victory O. Olutuase, Chinwe J. Iwu-Jaja, Cynthia P. Akuoko, Emmanuel O. Adewuyi and Vishnu Khanal
Citation: BMC Public Health 2022 22:11
Content type: Research
Published on: 5 January 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresnotes/content
(Accessed 08 Jan 2022)

The geography of COVID-19 misinformation: using geospatial maps for targeted messaging to combat misinformation on COVID-19, South Africa
The proliferation of false information on COVID-19 mostly through social media is adversely affecting control efforts. The objective of this study was to identify areas where targeted effective messaging can b…
Authors: Lucy Chimoyi, Tonderai Mabuto, Tanyaradzwa Dube, Nasiphi Ntombela, Tshegang Nchachi, Dakalo Tshisebe, Candice M. Chetty-Makkan and Geoffrey K. Setswe
Citation: BMC Research Notes 2021 14:468
Content type: Research note
Published on: 24 December 2021

Cell
Jan 06, 2022 Volume 185 Issue 1 p1-220
https://www.cell.com/cell/current

Commentary
BRAIN 2.0: Transforming neuroscience
John Ngai
The NIH BRAIN Initiative is entering a new phase. Three large new projects—a comprehensive human brain cell atlas, a whole mammalian brain microconnectivity map, and tools for precision access to brain cell types—promise to transform neuroscience research and the treatment of human brain disorders.

Clinical Pharmacology & Therapeutics
Volume 111, Issue 1 Pages: 1-331 January 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

Real World Evidence
Editorial
Free Access
The “Coming of Age” of Real-World Evidence in Drug Development and Regulation
Peter K Honig
Pages: 11-14
First Published:16 December 2021